Adcytherix announced a €104 million Series A to propel its lead antibody‑drug conjugate program toward first‑in‑human studies. The French biotech raised the financing from institutional life‑science investors to support IND enabling work, toxicology, CMC scale‑up and initiation of early clinical testing. Adcytherix’ platform blends proprietary antibody engineering with optimized payload linkers aimed at improving therapeutic index and expanding target scope. The financing positions the company to de‑risk translational milestones that are critical for partnering or additional capital raises ahead of clinical proof of concept. Investors continue to back ADC platforms with differentiated payload/linker chemistry as the modality matures and new targets emerge outside traditional oncology indications.